Humana Coverage Policy For Gilenya Promotes Second-Line Use

Humana’s medical coverage policy for Novartis’ new multiple sclerosis drug Gilenya (fingolimod) requires prior authorization documenting the patient has already tried and failed treatment with other drugs.